[13] Nakase, T. and Miyaji, T. (2003) Localization of bone morphogenetic protein-2 in human osteoarthritic cartilage and osteophyte. Osteoarthritis Cartilage 11, 278–284.
[14] Chen, D. and Zhao, M. (2004) Bone morphogenetic proteins. Growth Factors 22, 233–241.
[15] Matsubara, T. and Kida, K. (2008) BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation. J. Biol. Chem. 283, 29119–29125.
[16] Katagiri, T. and Yamaguchi, A. (1994) Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127, 1755–1766.
[17] Yamaguchi, A. and Ishizuya, T. (1996) Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived storomal cell lines, ST2 and MC3T3-G2/PA6. Biochem. Biophys. Res. Commun. 220, 366–371.
[18] Mylona, E. and Jones, K.A. (2006) CD44 regulates myoblast migration and differentiation. J. Cell. Physiol. 209, 314–321.
[19] Ariyoshi, W. and Okinaga, T. (2014) High molecular weight hyaluronic acid regulates osteoclast formation by inhibiting receptor activator of NF-kappaB ligand through Rho kinase. Osteoarthritis Cartilage 1, 111–120.
[20] Schmidt, K. and Schinke, T. (2005) The high mobility group transcription factor Sox8 is a negative regulator of osteoblast differentiation. J. Cell Biol. 168, 899–910.
[21] Katagiri, T. and Imada, M. (2002) Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. Genes Cells 7, 949–960.
[22] Ohte, S. and Katagiri, T. (2011) A novel mutation of ALK2, L196p, found in the most benign case of fibrodysplasia ossificans progressive activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H. Biochem. Biophys. Res. Commun. 407, 213–218.
[23] Bourrguignon, L.Y. and Iida, N. (1995) Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis. J. Neurooncol. 26, 201–208.
[24] Martin, G.S. (2003) Cell signaling and cancer. Cancer Cell 4, 167–174.
[25] Parri, M. and Chiarugi, P. (2010) Rac and Rho GTPases in cancer cell motility control. Cell Commun. Signal. 8, 23.
[26] Yoshida, T. and Clark, M.F. (2009) The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival. J. Cell. Biochem. 106, 896–902.
[27] Kazmers, N.H. and Yoshida, T. (2009) Rho GTPase signaling and PTH3-34, but not PTH 1–34, maintain the actin cytoskeleton and antagonize bisphosphonate effects in mouse osteoblastic MC3T3-E1 cells. Bone 45, 52–60.
[28] Yang, Y.S. and Tian, Y.J. (2011) Mechanisms by which the inhibition of specific intracellular signaling pathways increase osteoblast proliferation on apatite surfaces. Biomaterials 32, 2851–2861.
[29] Yoshikawa, H. and Yoshioka, K. (2009) Stimulation of ectopic bone formation in response to BMP-2 by Rho kinase inhibitor: a pilot study. Clin. Orthopedics Related Res. 467, 3087–3095.
[30] Hagihara, M. and Endo, M. (2011) Neogenin, a receptor for bone morphogenetic proteins. J. Biol. Chem. 286, 5157–5165.
[31] Kaneshiro, S. and Ebina, K. (2013) IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. J. Bone Miner. Metab.
[32] Moskowitz, R. and Altman, R. (2004) Intra-articular hyaluronic acid for treatment of osteoarthritis of the knee. JAMA 291, 1440–1441, author reply 1–2.
[33] Akmal, M. and Singh, A. (2005) The effects of hyaluronic acid on articular chondrocytes. Bone Joint J. 87, 1143–1149.
[34] Chard, J. and Lohmander, S. (2005) Osteoarthritis of the knee. Clin. Evid. 14, 1506–1522.
[35] van der Kraan, Peter M. and van den Berg, Wim B. (2006) Review Osteophytes: relevance and biology. Osteoarthritis Cartilage 15, 237–244.
[36] Gobezie, R. and Kho, A. (2007) High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res. Ther. 9, R36.

Please cite this article in press as: Kaneko, K., et al. Hyaluronan inhibits BMP-induced osteoblast differentiation. FEBS Lett. (2015), http://dx.doi.org/10.1016/j.febslet.2014.12.031